A practical approach to the management of lower urinary tract symptoms among men

被引:10
作者
Woo, Henry H. [1 ,2 ]
Gillman, Michael P. [3 ]
Gardiner, Robert [4 ]
Marshall, Villis [5 ]
Lynch, William J. [6 ]
机构
[1] Sydney Adventist Hosp, Sydney Urol Associates, Sydney, NSW, Australia
[2] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia
[3] Shore St W Med Ctr, Brisbane, Qld, Australia
[4] Univ Queensland, Brisbane, Qld, Australia
[5] Univ Adelaide, Fac Hlth Sci, Adelaide, SA, Australia
[6] St George Med Ctr, Dept Urol, Sydney, NSW, Australia
关键词
BENIGN PROSTATIC HYPERPLASIA; THERAPY; FINASTERIDE; PREVENTION; PREVALENCE; COMMUNITY; UPDATE;
D O I
10.5694/j.1326-5377.2011.tb03185.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Lower urinary tract symptoms (LUTS) are common among Australian men over the age of 45 years; most men with LUTS will have benign prostatic hyperplasia (BPH), overactive bladder (OAB), or both. The cause of LUTS should be diagnosed by assessing symptom severity and excluding of medical or pharmaceutical causes. All men with LUTS should undergo digital rectal examination; other diagnostic tools include urine and blood testing, voiding charts and imaging. Depending on disease severity, impact on quality of life, patient preference, presence of complications and fitness for surgery, BPH is managed with watchful waiting, pharmacotherapy (alpha-blockers or 5-alpha-reductase inhibitors), minimally invasive surgical therapies or surgery. OAB is initially treated with behavioural therapy; if this is ineffective, pharmacotherapy (usually antimuscarinics) can be used. Patients with LUTS with a provisional diagnosis other than BPH or OAB, or with complications or poor response to pharmacotherapy, should be referred to a urologist. MJA 2011; 195:34-39
引用
收藏
页码:34 / 39
页数:6
相关论文
共 25 条
  • [1] The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society
    Abrams, P
    Cardozo, L
    Fall, M
    Griffiths, D
    Rosier, P
    Ulmsten, U
    van Kerrebroeck, P
    Victor, A
    Wein, A
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2002, 187 (01) : 116 - 126
  • [2] Alpha-blockade therapy for benign prostatic hyperplasia:: From a nonselective to a more selective alpha1A-adrenergic antagonist
    Beduschi, MC
    Beduschi, R
    Oesterling, JE
    [J]. UROLOGY, 1998, 51 (06) : 861 - 872
  • [3] Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials
    Boyle, P
    Gould, AL
    Roehrborn, CG
    [J]. UROLOGY, 1996, 48 (03) : 398 - 405
  • [4] Bruskewitz Reginald C, 2003, Rev Urol, V5, P72
  • [5] *CONT FDN AUSTR, 2011, BLADD TRAIN
  • [6] EAU guidelines on benign prostatic hyperplasia (BPH)
    de la Rosette, JJMCH
    Alivizatos, G
    Madersbacher, S
    Perachino, M
    Thomas, D
    Desgrandchamps, F
    De Wildt, M
    [J]. EUROPEAN UROLOGY, 2001, 40 (03) : 256 - 263
  • [7] Minimally Invasive Therapy of Lower Urinary Tract Symptoms
    Donnell, Robert F.
    [J]. UROLOGIC CLINICS OF NORTH AMERICA, 2009, 36 (04) : 497 - +
  • [8] Long-term effects of finasteride on prostate specific antigen levels: Results from the Prostate Cancer Prevention Trial
    Etzioni, RD
    Howlader, N
    Shaw, PA
    Ankerst, DP
    Penson, DF
    Goodman, PJ
    Thompson, IM
    [J]. JOURNAL OF UROLOGY, 2005, 174 (03) : 877 - 881
  • [9] Detrusor instability in men: Correlation of lower urinary tract symptoms with urodynamic findings
    Hyman, MJ
    Groutz, A
    Blaivas, JG
    [J]. JOURNAL OF UROLOGY, 2001, 166 (02) : 550 - 552
  • [10] Treatment for benign prostatic hyperplasia among community dwelling men: The Olmsted County study of urinary symptoms and health status
    Jacobsen, SJ
    Jacobson, DJ
    Girman, CJ
    Roberts, RO
    Rhodes, T
    Guess, HA
    Lieber, MM
    [J]. JOURNAL OF UROLOGY, 1999, 162 (04) : 1301 - 1306